Arcus Biosciences, Inc.
RCUS· NYSE
Released Aug 7, 2023, before the open
10-Q filed Aug 7, 2023, 38 days after period end · 0000950170-23-038760
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $29.00M | $27.00M | $9.46M | $1.75M |
| Net Income | -$75.00M | -$67.00M | -$75.97M | -$45.07M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$1.04 |
| -$0.93 |
| -$1.09 |
| -$0.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.